

PATENT APPLICATION

THE UNITED STATES PATENT AND TRADEMARK OFFICE

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC

1050 Connecticut Avenue, N.W.,

Suite 600

Washington, DC 20036-5339 Telephone: (202) 857-6000 Facsimile: (202) 638-4810 Docket No.

P108129-08004

Date:

Filed concurrently

Examiner:

Berman, A.

Art Unit:

<u>1615</u>

BOX CPA

CONTINUED PROSECUTION APPLICATION TRANSMITTAL UNDER RULE 1.53(d)

Commissioner for Patents Washington, D.C. 20231

Sir:

Transmitted herewith under 37 C.F.R. §1.53(d) is a request for filing a

□ Continuation

☐ Divisional

continued prosecution application of prior pending Application No. 09/125,114, filed August 18, 1998,

For (Title):

DOSAGE FORM OF IBUPROFEN

(Amended Title):

By (Inventors):

Ian Ashley PRICE

- 1. \square Abandon said prior application as of the filing date accorded this application.

CLAIMS REMAINING IN THE APPLICATION AFTER ENTRY OF ANY PRELIMINARY AMENDMENT OR AMENDMENT UNDER 37 C.F.R. §1.116 NOTED BELOW

FOR:	NO. FILED	NO. EXTRA	
BASIC FEE			
TOTAL CLAIMS	38 - 20	= 18	
INDEP CLAIMS	5 - 3	= 2	
☐ MULTIPLE DEPENDENT CLAIMS PRESENTED			

* If the difference is less than zero, enter "0". 03/28/2001 RHARIS1 00000074 09125114

SMALL ENTITY

RATE FEE OR
\$ 355 OR

x 9 = \$ OR

x 40 = \$ OR

+135 = \$ OR

\$

OR

TOTAL

OTHER THAN A SMALL ENTITY

RATE	FEE	
	\$ 710	
x 18	\$ 324.00	
x 80	\$ 160:00	
+270	\$	
TOTAL	\$ 1,194.00	

02 FC:131 03 FC:102 04 FC:103

710.00 OP 160.00 OP

324.00 OP

Rule 1.53(d) Continued Prosecution Application of U.S. Application No. 09/125,114 Filed August 18, 1998

3.		A check in the amount of \$1,194.00 to cover the filing fee is attached. The Commissioner is hereby authorized to charge any other fees that may be required to complete this filing, or to credit any overpayment, to Deposit Account No. 01-2300.	
4.		No fee is attached. Please do not charge our deposit account.	
5.		Cancel in this application claims of the prior application before calculating the filing fee. At least one independent claim is retained for filing purposes.	
6.		Please enter in the present application the Amendment Under 37 CFR §1.116 with any attachments filed on in said prior application, which was not entered therein.	
7.		This application is filed by fewer than all the inventors named in the prior application (37 C.F.R §1.53(d)(4)). Delete the following inventor(s) named in the prior application:	
8.	\boxtimes	A Preliminary Amendment is enclosed. Claims added by this Amendment are properl numbered consecutively beginning with the number next following the highest numbered claim in the prior application.	
9.	\boxtimes	A Request for Reconsideration of Information Disclosure Statement is attached update from December 12, 2000 Response.	
10.		Small entity status:	
		a. A small entity statement is attached.	
		 b. A small entity statement was filed in the parent application and such status is still proper and desired. 	
		C. Small entity status is no longer claimed.	
11.		Other:	
12.	\boxtimes	Address all future communications to:	

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC 1050 CONNECTICUT AVENUE, N.W., SUITE 600 WASHINGTON, D.C. 20036-5339

Respectfully submitted,

Robert K. Carpenter Registration No. 34,794

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC 1050 Connecticut Avenue, N.W., Suite 600 Washington, D.C. 20036-5339

Tel: (202) 857-6000 Fax: (202) 638-4810





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

PRICE

Group Art Unit: 1615

Application No.: 09/125,114

Examiner: Berman, A.

Filed: August 18, 1998

Attorney Dkt. No.: 108129-08004

For: DOSAGE FORM OF IBUPROFEN

RECEIVED

PRELIMINARY AMENDMENT

MAR 2 9 2001

OFFICE OF PETITIONS

Commissioner for Patents Washington, D.C. 20231

Date: March 27, 2001

Sir:

Prior to initial examination of the application, please amend the above-identified application as follows:

IN THE CLAIMS:

Please add new claim 38 as follows:

--38. A dosage form according to claim 1 consisting of a powder mixture of a racemic ibuprofen medicament, compressible filler component, a discrete disintegrating component and a alkali metal carbonate or bicarbonate.--